Linagliptin And Metformin

Introduction Overview

Generic Name

linagliptin and metformin

Brand Name

Jentadueto XR

Dosage Form

Extended-release oral tablet

Drug Class

Antidiabetic combinations

Pharmacokinetics

Absorption:
Jentadueto XR combines linagliptin and metformin hydrochloride extended-release in a fixed-dose oral tablet designed for once-daily administration. Following oral administration, metformin XR demonstrates slower and more prolonged absorption compared to immediate-release metformin, leading to more stable plasma concentrations and reduced peak concentrations, thereby minimizing gastrointestinal side effects. Linagliptin exhibits rapid absorption but with a bioavailability of approximately 30%, with peak plasma concentrations achieved in 1.5 hours. The extended-release formulation of metformin allows for absorption primarily in the small intestine over an extended period, ensuring sustained systemic exposure. Food intake does not significantly affect linagliptin absorption but may delay metformin XR absorption slightly without reducing overall bioavailability.

Distribution:
Linagliptin displays a large volume of distribution (approximately 1110 L), indicating extensive tissue distribution, with extensive binding (approximately 70%) to plasma proteins. Metformin has a smaller volume of distribution (around 63-276 L) due to its hydrophilic nature and is not significantly bound to plasma proteins. Neither linagliptin nor metformin extensively binds to erythrocytes. Linagliptin's distribution is characterized by partitioning into kidney, liver, and plasma, correlating with its sites of action. The fixed-dose combination does not alter the distribution profile of the individual components.

Metabolism:
Linagliptin is primarily metabolized via CYP3A4 enzymes to inactive metabolites, with approximately 10% metabolized; the majority (around 80%) is eliminated unchanged. Metformin undergoes negligible hepatic metabolism and is excreted mainly unchanged, indicating minimal metabolic interaction between the components. The combination formulation retains these properties consistent with the individual drugs, reducing potential for metabolic drug-drug interactions.

Elimination:
Linagliptin elimination is predominantly fecal (approximately 80%) with about 5% renal excretion. It has a terminal half-life of approximately 12 hours but exhibits prolonged pharmacodynamic effects allowing for once-daily dosing. Metformin is eliminated unchanged primarily via renal excretion through active tubular secretion with a half-life of approximately 6.2 hours. Renal clearance of metformin is higher than creatinine clearance, indicating active secretion. The extended-release formulation may prolong elimination characteristics compared to immediate release. Clinical considerations include dose adjustments in renal impairment due to metformin accumulation risk and attention to lactic acidosis.
Overall, the pharmacokinetic profiles of linagliptin and metformin in Jentadueto XR maintain the individual drug characteristics, enabling combined therapeutic efficacy with manageable safety profiles.

Dosage Forms

Available Dosage Forms:
Jentadueto XR is available as extended-release tablets formulated as fixed-dose combinations of linagliptin and metformin hydrochloride extended-release. The specific dosage strengths include:
- Linagliptin 2.5 mg / Metformin XR 500 mg
- Linagliptin 2.5 mg / Metformin XR 1000 mg

Dosages for Adults and Adolescents:
Jentadueto XR is indicated for adults with type 2 diabetes mellitus as an adjunct to diet and exercise. The usual starting dose depends on prior metformin therapy or linagliptin exposure. Typical starting doses are:
- One tablet containing 2.5 mg linagliptin and 500 mg metformin XR once or twice daily with meals.
- Dose titration may occur at intervals of 1 to 2 weeks, individually adjusting metformin levels based on glycemic response and tolerability.
The maximum recommended dose of metformin XR in combination is generally 2000 mg per day. Linagliptin dose remains constant at 5 mg total daily dose (2.5 mg twice daily or 5 mg once daily). Dosage adjustments should consider renal function.

Specific Patient Populations:
- Renal Impairment: Jentadueto XR is contraindicated in patients with severe renal impairment (eGFR below 30 mL/min/1.73m²) due to metformin-associated lactic acidosis risk. Dose adjustment or avoidance is warranted for moderate renal impairment.
- Elderly: Caution advised in patients 65 years or older because of increased lactic acidosis risk, requiring renal function monitoring.
- Hepatic Impairment: Use cautiously or avoid due to risk of lactic acidosis.
- Pediatric: Safety and efficacy not established in patients under 18 years.

Clinical administration guidelines emphasize taking Jentadueto XR with meals to reduce gastrointestinal adverse effects and maintaining adherence to diet, exercise, and glucose monitoring. The extended-release formulation reduces dosing frequency, improving compliance compared to immediate-release metformin combinations.

Mechanism Of Action

Jentadueto XR is a combination oral antidiabetic medication comprising linagliptin and metformin extended-release, targeting complementary pathways to improve glycemic control in type 2 diabetes mellitus.

Linagliptin is a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4), an enzyme responsible for degrading incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, linagliptin prolongs incretin activity, which leads to enhanced glucose-dependent insulin secretion from pancreatic beta cells and suppression of glucagon release from alpha cells during hyperglycemia. This results in reduced hepatic glucose production and improved postprandial glucose metabolism without causing hypoglycemia.

Metformin’s principal mechanism involves decreasing hepatic gluconeogenesis, thereby lowering endogenous glucose production, particularly in the liver. Metformin also increases insulin sensitivity by enhancing peripheral glucose uptake and utilization, and it delays intestinal glucose absorption. Its action at the cellular level activates AMP-activated protein kinase (AMPK), a key regulator of cellular energy metabolism, contributing to its antihyperglycemic effects.

The combination in Jentadueto XR yields additive and complementary mechanisms: metformin reduces basal hepatic glucose output and enhances insulin sensitivity, while linagliptin enhances incretin effects, optimizing glucose-dependent insulin secretion and glucagon suppression. This dual action improves fasting and postprandial glucose levels.

Clinical studies demonstrate that this combination improves glycated hemoglobin (HbA1c) levels more effectively than either agent alone, with a low risk of hypoglycemia and no significant weight gain. The extended-release formulation of metformin ensures tolerability through gradual drug release, enhancing patient adherence and minimizing gastrointestinal side effects. Comparative pharmacology suggests superiority over monotherapy or some other antidiabetic classes due to the targeting of multiple pathophysiological defects in type 2 diabetes.

Pharmacological Actions

Inhibits dipeptidyl peptidase-4 (DPP-4) enzymatic activity, increasing endogenous incretin hormone levels.
Enhances glucose-dependent insulin secretion from pancreatic beta cells via incretin pathway potentiation.
Suppresses inappropriate postprandial glucagon secretion, reducing hepatic glucose output.
Decreases hepatic gluconeogenesis and endogenous glucose production through metformin-mediated AMPK activation.
Improves peripheral insulin sensitivity, facilitating increased glucose uptake in muscle and adipose tissues.
Delays intestinal absorption of glucose, contributing to postprandial glycemic control.
Reduces fasting and postprandial blood glucose levels in patients with type 2 diabetes.
Exerts antihyperglycemic effects without causing significant hypoglycemia due to glucose-dependent action.
Provides additive glucose-lowering effects through combined mechanisms of linagliptin and metformin.
Extended-release metformin formulation improves gastrointestinal tolerability and sustained plasma levels.
Modulates key metabolic pathways involved in energy homeostasis via activation of AMPK by metformin.
Contributes to improved glycemic parameters including HbA1c reduction and fasting plasma glucose control.

Therapeutic Or Clinical Uses

Management of type 2 diabetes mellitus in adults to improve glycemic control.
Adjunctive therapy combined with diet and exercise in patients inadequately controlled on metformin or linagliptin monotherapy.
Alternative for patients inadequately controlled with metformin alone requiring additional glycemic control.
Appropriate for patients needing combination oral therapy with complementary mechanisms of action.
Treatment option for patients with contraindications or intolerance to other antidiabetic agents.
Beneficial in patients concerned about hypoglycemia risk or weight gain associated with other agents.
Used to reduce HbA1c levels effectively in patients with hyperglycemia secondary to insulin resistance and beta-cell dysfunction.
Therapy to improve both fasting and postprandial glucose levels simultaneously.
May assist in delaying the progression of type 2 diabetes complications through improved metabolic control.
Part of a comprehensive treatment regimen including lifestyle modification to optimize glucose control.

Side Or Adverse Effects

Gastrointestinal disturbances such as diarrhea, nausea, vomiting associated primarily with metformin component.
Upper respiratory tract infections, including sore throat and nasopharyngitis, reported with linagliptin use.
Potential risk of hypoglycemia, especially when combined with other glucose-lowering agents; however, low incidence when used alone.
Rare cases of pancreatitis characterized by severe abdominal pain radiating to the back, nausea, and vomiting.
Lactic acidosis, a rare but potentially fatal condition associated with metformin accumulation, presenting with muscle pain, respiratory distress, or fatigue.
Severe allergic reactions including urticaria, rash, itching, and angioedema possibly attributable to linagliptin.
Serious skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis reported rarely.
Joint pain and musculoskeletal discomfort, some severe and ongoing, observed during linagliptin therapy.
Signs of heart failure including shortness of breath, peripheral edema, and rapid weight gain reported in rare instances.
Vitamin B12 deficiency may occur with long-term metformin use, requiring monitoring.
Elevated liver enzymes and hepatic dysfunction reported infrequently; close monitoring advised in patients with hepatic impairment.
Potential for acute kidney injury, especially in patients with pre-existing renal disease or dehydration.
Headache and dizziness reported in some patients.
Fatigue and weakness may occur, particularly in cases progressing to lactic acidosis.
Rare instances of pancreatitis and other serious gastrointestinal adverse effects necessitate prompt discontinuation.

Precautions

Assess renal function prior to initiation and periodically during therapy; avoid use in severe renal impairment.
Monitor for signs and symptoms of lactic acidosis, especially in patients with risk factors such as advanced age, liver disease, or alcohol abuse.
Use cautiously in patients with history of pancreatitis or gallbladder disease.
Discontinue temporarily prior to iodinated contrast imaging procedures to reduce risk of acute renal failure and lactic acidosis.
Caution in patients with congestive heart failure, particularly when treated with medications affecting renal function.
Inform patients about the symptoms of hypoglycemia and educate on appropriate management strategies.
Avoid alcohol consumption during treatment due to increased risk of lactic acidosis and hypoglycemia.
Pregnancy category B; use only if clearly needed and under strict medical supervision.
Not approved for pediatric patients under 18 years of age; safety and efficacy not established.
Advise patients against crushing or chewing the extended-release tablets to maintain proper release profile.
Monitor vitamin B12 levels during prolonged therapy for potential nutritional deficiencies.
Consider dose adjustments or discontinuation in patients undergoing surgical procedures or experiencing acute illness.
Ensure comprehensive patient education on lifestyle interventions concomitant with drug therapy.
Use with caution in hepatic impairment due to impaired lactate metabolism.
Evaluate potential drug interactions meticulously to avoid reduced efficacy or increased adverse effect risks.

Warnings

Contraindicated in patients with severe renal impairment (eGFR below 30 mL/min/1.73 m²) due to risk of metformin-associated lactic acidosis.
Do not use in patients with diabetic ketoacidosis; insulin therapy is preferred in such cases.
Risk of lactic acidosis increased in presence of acute or chronic metabolic acidosis, including due to alcohol intoxication or hypoxia.
Use caution in elderly patients (65 years or older) who have decreased renal function and increased lactic acidosis risk.
Stop Jentadueto XR immediately and seek emergency care if symptoms of lactic acidosis occur, including unusual muscle pain, respiratory distress, dizziness, or severe weakness.
Potential for serious allergic reactions, including anaphylaxis and severe cutaneous adverse reactions.
Pancreatitis has been reported; discontinue therapy if pancreatitis is suspected or confirmed.
Regular monitoring recommended in patients with history of cardiovascular disease due to reported heart failure symptoms.
Temporary discontinuation necessary before radiologic studies involving iodinated contrast agents to prevent acute renal injury.
Avoid abrupt discontinuation without medical guidance to prevent destabilization of glycemic control.
Monitor for signs of hypoglycemia, especially when taken in combination with insulin or insulin secretagogues.
Hypoglycemia risk if dose changes not managed appropriately with concomitant diabetes medications.
The medication may stimulate ovulation; women with fertility concerns should consult a healthcare provider.
Not studied for use in type 1 diabetes; use in this population is contraindicated.
Adherence to dosing schedule with meals critical to minimize gastrointestinal adverse effects.

Contraindication

Known hypersensitivity to linagliptin, metformin, or any component of Jentadueto XR.
Severe renal impairment (eGFR less than 30 mL/min/1.73 m²) or acute renal failure.
Diabetic ketoacidosis, with or without coma.
Acute or chronic metabolic acidosis including lactic acidosis.
Known hypersensitivity or allergy to any biguanide or DPP-4 inhibitors.
Patients undergoing radiologic studies involving intravascular iodinated contrast materials unless temporarily discontinued.
Severe hepatic impairment, due to increased risk of lactic acidosis.
Conditions predisposing to tissue hypoxia such as cardiac or respiratory failure.
Alcoholism or alcohol abuse due to increased lactic acidosis risk.
acute conditions with potential hypoxemia such as shock or sepsis.
Pregnancy category advises cautious use; not a direct contraindication but requires evaluation.
Not indicated for treatment of type 1 diabetes or diabetic coma.
In pediatric patients under 18 years due to lack of safety and efficacy data.

Drug Interactions

Concomitant use with other antidiabetic agents (insulin, sulfonylureas) may increase hypoglycemia risk.
Medications impairing renal function (e.g., NSAIDs, diuretics, ACE inhibitors) may elevate metformin plasma levels and lactic acidosis risk.
Cationic drugs eliminated by renal tubular secretion (e.g., cimetidine, ranitidine) may reduce metformin clearance.
Drugs delaying gastric emptying or affecting metformin absorption can alter glycemic control.
Alcohol potentiates metformin's effect on lactate metabolism, increasing lactic acidosis risk.
Strong CYP3A4 inducers or inhibitors have minimal impact on linagliptin but system monitoring advised.
Contrast agents used for radiologic studies can cause acute renal impairment; Jentadueto XR should be withheld.
Beta-blockers, clonidine, and sympatholytics may mask hypoglycemia symptoms.
Furosemide and other diuretics may precipitate dehydration, increasing lactic acidosis risk.
Thiazide diuretics and corticosteroids may exacerbate hyperglycemia, counteracting therapeutic effects.
Drugs causing hypoglycemia require dose adjustments when combined with Jentadueto XR.
Other herbal products and vitamins may interact; patient medication reconciliation essential.
Careful monitoring needed when combining with drugs that affect blood glucose levels.
Nonsteroidal anti-inflammatory drugs may raise renal risk; avoid concurrent use in susceptible patients.
Medications affecting cytochrome P450 enzymes warrant clinical vigilance though linagliptin metabolism minimally affected.

Preparations Of The Drug

Jentadueto XR 2.5 mg linagliptin / 500 mg metformin hydrochloride extended-release tablets, film-coated.
Jentadueto XR 2.5 mg linagliptin / 1000 mg metformin hydrochloride extended-release tablets, film-coated.
Extended-release formulation designed to provide controlled delivery of metformin over 24 hours.
Film-coated tablets intended for oral administration, swallowed whole with meals.
Available in blister packs and bottles, with stability maintained at room temperature away from moisture and heat.
Fixed-dose combination tablets developed to increase patient adherence through simplified dosing.
Packaging includes prescription labeling, patient medication guides, and storage instructions.
Approved for once-daily or twice-daily dosing depending on clinical needs and tolerability.
Manufactured under Good Manufacturing Practices ensuring consistent quality and potency.
Not available in chewable, liquid, or immediate-release tablet forms under the Jentadueto XR brand.
Supplied with medication guides addressing potential adverse effects, warnings, and precautions.
Sterile and non-sterile excipients included in tablet formulation to ensure stability and bioavailability.
Each tablet contains specified dosages precisely to meet therapeutic requirements of diabetic patients.
Available only by prescription, requiring practitioner assessment before initiation.
Complementary patient education materials provided to optimize therapeutic outcomes.